Sign Up for a Free Account
  • Updated 04.05.2021
  • Released 06.25.2004
  • Expires For CME 04.05.2024

Angelman syndrome

Introduction

Overview

Angelman syndrome is a neurodevelopmental disorder characterized by intellectual disability, epilepsy, ataxia, and a unique behavioral phenotype. In this article, the author discusses the diagnosis, prognosis, genetic counseling, and health surveillance of patients with Angelman syndrome. Also discussed are studies using models of Angelman syndrome, which provide insight into the pathoetiology and potential treatment of Angelman syndrome.

Key points

• Diagnosing Angelman syndrome has important implications for prognosis, genetic counseling, health surveillance, and, in some instances, specific symptomatic therapies.

• The number of genetic mechanisms that lead to Angelman syndrome and the paradigm for diagnostic testing has evolved as cytogenic and molecular technologies have been introduced.

• Molecular and genetic models are producing an increasingly comprehensive view of the mechanisms responsible for altered experience-dependent hippocampal and neocortical plasticity in this disorder.

• Understanding the genetic factors involved in the imprinting process has allowed researchers to target therapeutics that may show promise for treatment of this disorder.

Historical note and terminology

In 1965, Dr. Harry Angelman described 3 unrelated children who had in common severe intellectual disability, fits of laughter, ataxia, epilepsy, and similar physical features. Because of the quality of their movement, their particular facies, and the characteristic bouts of laughter, he felt they resembled “puppet children” (03), and further case reports referred to the condition as the “happy puppet syndrome.” In 1982, Williams and Frias suggested the eponymous “Angelman syndrome” as a less derisive-sounding alternative (110).

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com